MDT-AP-2024
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 120
- os_event
- false
- age_years
- 4.3
- sex
- F
- new_clusters
- C5
- umap1_2d
- 5.25673256
- umap2_2d
- 5.436262347
- umap1_3d
- 1.953698044
- umap2_3d
- 0.032695299
- umap3_3d
- -1.93406012
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.390
- HEDGEHOG_SIGNALING+0.280
- SPERMATOGENESIS+0.200
- XENOBIOTIC_METABOLISM+0.200
- CHOLESTEROL_HOMEOSTASIS+0.160
- OXIDATIVE_PHOSPHORYLATION+0.160
- PROTEIN_SECRETION+0.150
- FATTY_ACID_METABOLISM+0.140
- KRAS_SIGNALING_DN+0.140
- ADIPOGENESIS+0.120
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- INTERFERON_ALPHA_RESPONSE-0.450
- TGF_BETA_SIGNALING-0.430
- G2M_CHECKPOINT-0.410
- MITOTIC_SPINDLE-0.400
- UV_RESPONSE_DN-0.390
- WNT_BETA_CATENIN_SIGNALING-0.380
- E2F_TARGETS-0.370
- APOPTOSIS-0.350
- IL6_JAK_STAT3_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2407 | Med | Medulloblastoma | 0.851 |
| 2 | SRR1446092 | GTEX | — | 0.850 |
| 3 | SRR1467455 | GTEX | — | 0.844 |
| 4 | SRR1101421 | GTEX | — | 0.842 |
| 5 | SRR1354013 | GTEX | — | 0.833 |
| 6 | SRR1318426 | GTEX | — | 0.813 |
| 7 | SRR1317596 | GTEX | — | 0.811 |
| 8 | MDT-AP-1260 | Med | Medulloblastoma | 0.806 |
| 9 | SRR608574 | GTEX | — | 0.802 |
| 10 | SRR1452379 | GTEX | — | 0.801 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.390 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |
| MYOGENESIS | 0.010 | Inavolisib | — uncovered |